» Articles » PMID: 32174110

Kinetics of DNA Adducts and Abasic Site Formation in Tissues of Mice Treated with a Nitrogen Mustard

Overview
Specialty Toxicology
Date 2020 Mar 17
PMID 32174110
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Nitrogen mustards (NM) are an important class of chemotherapeutic drugs used in the treatment of malignant tumors. The accepted mechanism of action of NM is through the alkylation of DNA bases. NM-adducts block DNA replication in cancer cells by forming cytotoxic DNA interstrand cross-links. We previously characterized several adducts formed by reaction of bis(2-chloroethyl)ethylamine (NM) with calf thymus (CT) DNA and the MDA-MB-231 mammary tumor cell line. The monoalkylated N7-guanine (NM-G) adduct and its cross-link (G-NM-G) were major lesions. The cationic NM-G undergoes a secondary reaction through depurination to form an apurinic (AP) site or reacts with hydroxide to yield the stable ring-opened -substituted formamidopyrimidine (NM-Fapy-G) adduct. Both of these lesions are mutagenic and may contribute to secondary tumor development, a major clinical limitation of NM chemotherapy. We established a kinetic model with NM-treated female mice and measured the rates of formation and removal of NM-DNA adducts and AP sites. We employed liquid chromatography-mass spectrometry (LC-MS) to measure NM-G, G-NM-G, and NM-Fapy-G adducts in liver, lung, and spleen over 168 h. NM-G reached a maximum level within 6 h in all organs and then rapidly declined. The G-NM-G cross-link and NM-FapyG were more persistent with half-lives over three-times longer than NM-G. We quantified AP site lesions in the liver and showed that NM treatment increased AP site levels by 3.7-fold over the basal levels at 6 h. The kinetics of AP site repair closely followed the rate of removal of NM-G; however, AP sites remained 1.3-fold above basal levels 168 h post-treatment with NM. Our data provide new insights into NM-induced DNA damage and biological processing . The quantitative measurement of the spectrum of NM adducts and AP sites can serve as biomarkers in the design and assessment of the efficacy of novel chemotherapeutic regimens.

Citing Articles

Identification of early events in nitrogen mustard pulmonary toxicity that are independent of infiltrating inflammatory cells using precision cut lung slices.

Bellomo A, Herbert J, Kudlak M, Laskin J, Gow A, Laskin D Toxicol Appl Pharmacol. 2024; 486:116941.

PMID: 38677601 PMC: 11887942. DOI: 10.1016/j.taap.2024.116941.


Interaction of mitoxantrone with abasic sites - DNA strand cleavage and inhibition of apurinic/apyrimidinic endonuclease 1, APE1.

Minko I, Moellmer S, Luzadder M, Tomar R, Stone M, McCullough A DNA Repair (Amst). 2023; 133:103606.

PMID: 38039951 PMC: 11257150. DOI: 10.1016/j.dnarep.2023.103606.


Liquid Chromatography-Mass Spectrometry Screening of Cyclophosphamide DNA Damage In Vitro and in Patients Undergoing Chemotherapy Treatment.

Guidolin V, Jacobs F, MacMillan M, Villalta P, Balbo S Chem Res Toxicol. 2023; 36(8):1278-1289.

PMID: 37490747 PMC: 11231964. DOI: 10.1021/acs.chemrestox.3c00008.


Anthracyclines React with Apurinic/Apyrimidinic Sites in DNA.

Bellamri M, Terrell J, Brandt K, Gruppi F, Turesky R, Rizzo C ACS Chem Biol. 2023; 18(6):1315-1323.

PMID: 37200590 PMC: 10391585. DOI: 10.1021/acschembio.3c00033.


Comparative analysis of chlorambucil-induced DNA lesion formation and repair in a spectrum of different human cell systems.

Krassnig S, Maser M, Probst N, Werner J, Schlett C, Schumann N Toxicol Rep. 2023; 10:171-189.

PMID: 36714466 PMC: 9881385. DOI: 10.1016/j.toxrep.2023.01.010.


References
1.
Johnson L, Malayappan B, Tretyakova N, Campbell C, MacMillan M, Wagner J . Formation of cyclophosphamide specific DNA adducts in hematological diseases. Pediatr Blood Cancer. 2011; 58(5):708-14. PMC: 3204332. DOI: 10.1002/pbc.23254. View

2.
Rinne M, Caldwell D, Kelley M . Transient adenoviral N-methylpurine DNA glycosylase overexpression imparts chemotherapeutic sensitivity to human breast cancer cells. Mol Cancer Ther. 2004; 3(8):955-67. View

3.
Sharma M, Vijayaraghavan R, Ganesan K . Comparison of toxicity of selected mustard agents by percutaneous and subcutaneous routes. Indian J Exp Biol. 2009; 46(12):822-30. View

4.
Yan L, Bulgar A, Miao Y, Mahajan V, Donze J, Gerson S . Combined treatment with temozolomide and methoxyamine: blocking apurininc/pyrimidinic site repair coupled with targeting topoisomerase IIalpha. Clin Cancer Res. 2007; 13(5):1532-9. DOI: 10.1158/1078-0432.CCR-06-1595. View

5.
Douki T, Laporte G, Cadet J . Inter-strand photoproducts are produced in high yield within A-DNA exposed to UVC radiation. Nucleic Acids Res. 2003; 31(12):3134-42. PMC: 162242. DOI: 10.1093/nar/gkg408. View